Chargement de la fiche…
Chargement de la fiche…
MonRhumato.fr utilise des cookies pour mesurer l'audience (statistiques) et améliorer le site. Aucune donnée de santé identifiable n'est jamais collectée. Politique de confidentialité.
Votre choix est conservé 13 mois (durée max CNIL). Vous pouvez le modifier à tout moment via Préférences cookies.
3 raisons identifiées
Auteur de référence en rhumatologie
35 articles scientifiques publiés — un praticien à la pointe de la recherche
Disponibilité géographique
2 lieux d'exercice — choisissez celui qui vous arrange
Délais de RDV courts dans la région
146.3 rhumatos / 100 000 hab. — département bien doté
✨ Génération du profil synthétique IA en cours…
CHRU NANCY - HOPITAL CENTRAL
29 AV DE LATTRE DE TASSIGNY CO 60034, 54035 NANCY CEDEX
HOPITAL DE MERCY - CHR METZ THIONVILLE
1 ALL DU CHATEAU CS 45001 ARS-LAQUENEXY, 57085 METZ CEDEX 03
Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.
Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).
Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).
Stem cells translational medicine · 2021
Abstract Buerger's disease or thromboangiitis obliterans is a type of obstructive vascular diseases categorized as vasculitis and usually present in 95% of young smoker men. The main pathogenetic mechanism is interplay between immune system and inflammation. Earlier our phase II study has shown that Stempeucel is safe when injected at 2 million cells/kg body weight by virtue of its anti-inflammatory, immunomodulatory, and angiogenetic properties. The present study was conducted to further assess the safety and efficacy of Stempeucel in critical limb ischemia due to Buerger's disease after obtaining approval from Indian FDA based on the data generated in the phase II study. This is an open label, multicenteric phase IV PMS study conducted across India with experienced vascular surgeons. Fifty patients of critical limb ischemia due to Buerger's disease with Rutherford III-5 or III-6 were included in the study and each individual received a dose of 2 million cells/kg body weight of Stempeucel in the calf muscles and around the ulcer. These patients were evaluated over 12 months from drug administration. The present study showed the continued long term efficacy over a period of 12 months follow up in these patients corroborating the result obtained in the previous phase II studies. There was significant improvement in rest pain, ankle systolic pressure, and ankle brachial pressure index with accelerated ulcer healing. In conclusion, the present study shows that the intramuscular administration of Stempeucel continues to be safe, tolerable, and effective alternative treatment in patients with Buerger's disease.
The Journal of the Association of Physicians of India · 2022
Medicina (Kaunas, Lithuania) · 2022
Background and Objectives: Neonatal mortality is a global public health issue, disproportionately affecting low- and middle-income nations. Although Romania is a high-income nation, according to the European Union’s most recent demographic data, it had the second-highest infant death rate in 2019. Although significant progress has been made in the last three decades in lowering newborn mortality, more initiatives to accelerate progress are required to meet the 2030 Sustainable Development Goals (SDG) objective. Therefore, we aimed to develop an observational study to determine the influence of maternal factors on in-hospital neonatal intensive care unit admission and mortality in premature infants born in western Romania. While newborn mortality has decreased globally, the pace of decline is far less than what is desired. Materials and Methods: A retrospective study comprising 328 premature patients and 422 full-term newborns, was developed at a tertiary obstetrics and gynecology clinic in western Romania, comprising the period of the last 24 months before the COVID-19 pandemic and the first 24 months of the pandemic. Results: The following variables were identified as statistically significant risk factors for neonatal intensive care unit admission: age > 35 years, OR = 1.59; twin births, OR = 1.14; low gestational age, OR = 1.66; preeclampsia, OR = 2.33; and peripartum infection, OR = 2.25. The same risk factors, with the exception of twin births, were significantly associated with in-hospital neonatal mortality. Except for a longer duration of maternal hospitalization and neonatal therapy with surfactant, steroids, and antibiotics, the COVID-19 pandemic did not cause significant differences in the evolution and outcomes of preterm newborns. Conclusions: The major maternal risk factors for NICU admission were advanced age, twin pregnancy, low gestational age, preeclampsia, and peripartum infection. Additionally, these characteristics contributed to a high likelihood of death, despite adequate access to medical care and advanced life support for the neonates. Understanding the causes of morbidity and death in neonates admitted to the neonatal intensive care unit enables better prioritization and planning of health services, resource reallocation, and care quality improvement.
Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).
The Journal of international medical research · 2026 · Journal Article
Been Sayeed SKJ, M M, Mahmud R, Rahman S, et al.
Journal of clinical medicine · 2026 · Journal Article
Hamod A, Grigore M, Vasilache IA, Ursu RG, et al.
Bioinformation · 2025 · Journal Article
G N, M SSL, V S, K S, et al.
Veterinary medicine and science · 2024 · Journal Article
El-Katcha MI, Soltan MA, Ghamry HI, El-Nahas AF, et al.
Medicina (Kaunas, Lithuania) · 2024 · Journal Article
Talida V, Tudor SS, Mihaela I, Daniela-Rodica M, et al.
Brain, behavior, & immunity - health · 2023 · Journal Article
Graïc JM, Finos L, Vadori V, Cozzi B, et al.
PLoS neglected tropical diseases · 2023 · Journal Article
Guttapadu R, Prakash N, M A, Chatterjee R, et al.
medRxiv : the preprint server for health sciences · 2022 · Preprint
Ghosh P, Niesen MJM, Pawlowski C, Bandi H, et al.
Medicina (Kaunas, Lithuania) · 2022 · Journal Article
Ilyes SG, Chiriac VD, Gluhovschi A, Mihaela V, et al.
JMIR research protocols · 2025 · Journal Article
M A, Ahmad A, A A, Raj LS, et al.
Acta oncologica (Stockholm, Sweden) · 2025 · Journal Article
Søby S, Prestwich R, Gyldenkerne N, Maare C, et al.
Diabetology & metabolic syndrome · 2022 · Journal Article
Călin P, Viorel M, Luchiana P, Mihaela C, et al.
GeroScience · 2026 · Journal Article
Mihaela A, Cercel A, Doeppner TR, Hermann DM, et al.
International journal of molecular sciences · 2026 · Systematic Review
Dragos F, Livia SI, Gabriel PF, Bogdan C, et al.
Diagnostics (Basel, Switzerland) · 2025 · Journal Article
Săndulescu MS, Veliscu Carp A, Vrabie SC, Anișoara S, et al.
Clinical rheumatology · 2025 · Journal Article
A K, M EA, M H, H A, et al.
Rheumatology and immunology research · 2024 · Journal Article
Datta D, Khatun M, Bankura B, Sarkar M, et al.
Medicina (Kaunas, Lithuania) · 2025 · Journal Article
Poamaneagra SC, Axinte S, Anton C, Tătăranu E, et al.
Research in sports medicine (Print) · 2025 · Journal Article
Dinescu SC, Stoica D, Bita CE, Morosanu A, et al.
International journal of molecular sciences · 2026 · Systematic Review
Dragos F, Livia SI, Gabriel PF, Bogdan C, et al.
Diagnostics (Basel, Switzerland) · 2025 · Journal Article
Săndulescu MS, Veliscu Carp A, Vrabie SC, Anișoara S, et al.
JACC. Case reports · 2024 · Case Reports
Kharge JL, M UK, M L J, Newaskar AA, et al.
Stem cells translational medicine · 2021 · Clinical Trial, Phase IV
Gupta PK, Dutta S, Kala S, Nekkanti M, et al.
Cureus · 2023 · Case Reports
Munteanu I, Mihaela M, Popescu S, Slavu IM, et al.
Cureus · 2024 · Case Reports
Surapaneni D, Dasi SC, Sam N, M J
Physiotherapy · 2026 · Letter
Rashid FA, M RP
Clinical rheumatology · 2025 · Journal Article
Mohan A, Mohan A, Ramachandran A, Pulinilkunnathil JG, et al.
The Journal of the Association of Physicians of India · 2022 · Journal Article
Murugesan H, Cs G, Nasreen HS, Santhanam S, et al.
BMJ case reports · 2025 · Journal Article
Pathrot D, Nachappa AA, Mannual S, M SK
Indian journal of dermatology, venereology and leprology · 2023 · Letter
Rao AG, M N, Ch S, Jhawar J
Radiology case reports · 2023 · Case Reports
Lee ZR, Lai YK, M L, Khor LY, et al.
Diagnostics (Basel, Switzerland) · 2026 · Journal Article
Hamod A, Mihaela O, Grigore M, Vasilache IA, et al.
Cureus · 2025 · Journal Article
Nallaperumal S, V P, M C V, Pusapati LCV, et al.
The Lancet regional health. Europe · 2025 · Journal Article
Winkler P, Guerrero Z, Kågström A, Petrášová M, et al.
Cureus · 2022 · Case Reports
Chandra MS, G A M, M RK
Cureus · 2024 · Case Reports
Mohan A, Kuriakose SM, James L, G BT, et al.
Cureus · 2023 · Journal Article
M D, Kumar J, Ramalingam K